Latest Organofluorides Stories
EAST HANOVER, N.J., Nov. 28, 2012 /PRNewswire/ -- Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases. The American Society of Hematology (ASH) annual meeting in Atlanta, held December 8-11, will feature...
-- First publication of the global Phase III CORRECT and GRID study data of the oral multi-kinase inhibitor regorafenib TORONTO, Nov. 27, 2012 /CNW/ - Bayer HealthCare today announced that the results of two pivotal Phase III studies for regorafenib were published online in the journal The Lancet ahead of a future print publication. Data from the CORRECT (Metastatic Colorectal cancer treated with regorafenib or placebo after failure of standard therapy)...
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial. The treatment of gastrointestinal stromal tumor, or GIST, even in its advanced metastatic stage, has been dramatically improved with two oral targeted drugs – imatinib (Gleevec) and...
DETROIT, Nov. 9, 2012 /PRNewswire-USNewswire/ -- In October 2012, a fourth SAE International Cooperative Research Program (CRP) was launched by the automotive industry to further analyze the safety of the new mobile air conditioner refrigerant, R1234yf. The participants in the 2012 R1234yf CRP include Audi, BMW, Chrysler, Daimler, Ford, General Motors, Honda, Hyundai, Jaguar Land Rover, Mazda, PSA, Renault and Toyota. The previous three SAE International CRP's related to R1234yf...
CALGARY, Nov. 9, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced three poster presentations covering expanded results from: a Phase II clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours (REO 016), a Phase II clinical trial using intravenous administration of REOLYSIN( )in combination with...
WASHINGTON, Nov. 7, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the third quarter and nine months ended September 30, 2012. Key Highlights: The tasimelteon Non-24-Hour Disorder (Non-24) program continues towards the goal of a projected mid-2013 New Drug...
LOS ANGELES, Nov. 5, 2012 /PRNewswire/ -- Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today the launch of testing for ROS1 gene rearrangements. Recently, the Massachusetts General Hospital Cancer Center ("MGH") published studies showing that ROS1 driven tumors are sensitive to the FDA approved drug XALKORI®(1) (crizotinib)(2) to treat non-small-cell lung cancer ("NSCLC") patients with...
PARIS and TARRYTOWN, N.Y., Oct. 31, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from a Phase 2 trial of SAR236553/REGN727 in patients with primary hypercholesterolemia were published in the October 31, 2012 issue of the New England Journal of Medicine. The study enrolled patients with primary hypercholesterolemia with elevated LDL-C (greater than or equal to 100 mg/dL) who were on a...
Study finds that prasugrel may reduce cardiovascular events among patients managed medically after an angiogram for acute coronary syndrome A study has found that the anti-clotting medication prasugrel reduced cardiovascular events among patients who present with an acute coronary syndrome and are managed medically after an angiogram is performed to determine coronary anatomy. Results of the TRILOGY ACS trial, Angiographic Cohort were presented today at the 24th annual Transcatheter...
GlaxoSmithKline is experimenting with a new combination of cancer medications; Petra Rietschel, MD encourages such exploration. White Plains, New York (PRWEB) October 24, 2012 Bloomberg Businessweek reports that GlaxoSmithKline Plc has combined two medications designed to treat melanoma in an effort to slow the growth of the cancer. According to the article, a study has found that this combination has succeeded in limiting the progression of the disease more successfully than a...
